Peptide Reference Desk
Cagrilintide vs Pramlintide: “amylin analogue” is only the first line of the comparison
Cagrilintide and pramlintide belong to amylin-analogue research, but their molecular designs, exposure profiles and regulatory records differ.
Shared pathway, different products
Pramlintide is an approved amylin analogue with its own labels and clinical record. Cagrilintide is a long-acting amylin analogue developed with different structural modifications and a separate investigational evidence file. Calling both “amylin” hides the design work that separates them.
What belongs in a fair comparison
| Layer | Question |
|---|---|
| Molecule | What sequence, substitutions and acylation are present? |
| Formulation | Which single-agent or combination product was tested? |
| Evidence | Was the endpoint measured in a matched population? |
| Status | What is approved or investigational in this jurisdiction and date? |
CagriSema is not another name for cagrilintide
CagriSema refers to a combination development program involving cagrilintide and semaglutide. Results from the combination cannot be assigned to cagrilintide alone, and a research blend is not the same product as a sponsor-controlled trial formulation.
Verify with primary records
Use the primary paper, current regulator label or lot-linked analytical file for the claim it supports. A search result is a route to evidence, not the evidence itself.